Immatics und Editas Medicine schließen strategische Forschungskollaboration zur Kombination von gamma-delta T-Zelltherapien mit Gene-Editing-Technologien für die Behandlung von Krebs ab
June 07, 2022 07:00 ET
|
Immatics N.V.
Tübingen, Deutschland, Houston, Texas und Cambridge, Massachusetts, 7. Juni 2022 – Immatics N.V. (Nasdaq: IMTX, „Immatics“), ein Unternehmen, das sich auf die Entwicklung und Herstellung von...
CRISPR Therapies Pipeline Insights 2021: Analysis of Key Companies, Emerging Therapies, Recent Happenings and Futuristic Trends
April 12, 2021 20:30 ET
|
DelveInsight Business Research LLP
Los Angeles, USA, April 12, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapies Pipeline Insights 2021: Analysis of Key Companies, Emerging Therapies, Recent Happenings and Futuristic Trends The leading...
Editas Medicine Appoints Cynthia Collins as President and Chief Executive Officer
August 06, 2019 16:01 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that its Board of Directors has unanimously appointed...
Editas Medicine and BlueRock Therapeutics Enter Strategic Research Collaboration and Cross-Licensing Agreement to Combine Genome Editing and Cell Therapy Platforms
April 03, 2019 07:00 ET
|
Editas Medicine, Inc.
– Collaboration enables BlueRock to discover and develop engineered cell medicines broadly across neurology, cardiology and immunology – – Collaboration enables Editas Medicine to discover and...
Editas Medicine Supports Global Movement to Raise Awareness on Rare Disease Day®
February 28, 2019 09:00 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, announced today the Company is joining forces with the nearly 30 million...
Editas Medicine Names David Scadden, M.D., to Board of Directors
February 06, 2019 09:00 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Feb. 06, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that it has appointed David T. Scadden, M.D., to its Board...
Editas Medicine Announces Chief Executive Officer Transition
January 22, 2019 09:00 ET
|
Editas Medicine, Inc.
Katrine Bosley to Step Down as President and CEO Director Cynthia Collins to Serve as Interim CEO Board of Directors Initiates Search for Permanent Successor CAMBRIDGE, Mass., Jan. 22, 2019 ...
Editas Medicine Announces Publication in Nature Medicine of Data Supporting the Development of EDIT-101 to Treat Leber Congenital Amaurosis 10 (LCA10)
January 21, 2019 11:00 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Jan. 21, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the journal Nature Medicine published the comprehensive,...
Editas Medicine Reports on Recent Progress at J.P. Morgan Healthcare Conference
January 07, 2019 09:00 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) -- In a presentation to investors on Wednesday, January 9, 2019, at 9:00 a.m. PST at the 37th Annual J.P. Morgan Healthcare Conference, Editas...
Editas Medicine to Present at the 37th Annual J.P. Morgan Healthcare Conference
January 02, 2019 08:30 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview followed by a...